-
Barclays Says Acceleration For Amgen Could Be A Challenge
Thursday, July 28, 2016 - 11:18am | 432Read More...Amgen, Inc. (NASDAQ: AMGN) reported robust 2Q results on both the top and bottom lines, modestly beating expectations. Barclays’ Geoff Meacham maintained an Equal-Weight rating on the company, with a price target of $185. Further Acceleration Could Be Challenging “While we have fairly...
-
Citigroup Lowers Estimates Of Amgen's Aranesp
Tuesday, October 19, 2010 - 9:23am | 130Read More...Citigroup reports that the FDA Cardiorenal Advisory Committee meeting was largely in line with expectations and will lead to some restrictions on the starting dose for Aranesp (from Amgen, Inc. (NASDAQ: AMGN)) in pre-dialysis. “There is some chance that there will be an informed consent form as...
